KMT2A and acute myeloid leukemia: For combination studies, six primary AML samples were selected based on the presence of the most common favorable (e.g., NPM1) and unfavorable mutations (e.g., FLT3-internal tandem duplication (ITD) and KMT2A-PTD), in order to assess the efficacy of fadraciclib and its synergistic activity when combined with VEN, AraC, or AZA, towards these mutations.